Market Place
Sourcing Support
Spectrum to lay off R&D staff after FDA drug rejection
29 Nov 2022 //
BIOPHARMADIVE
Spectrum implodes after aharsh public slapdown and a CRL from Richard Pazdur
28 Nov 2022 //
ENDPTS
FDA hands Hanmi’s partner, Spectrum, a poziotinib CRL for supplementary data
25 Nov 2022 //
KOREABIOMED
Spectrum Provides Update on Poziotinib Following FDA Oncologic Advisory Meeting
22 Sep 2022 //
BUSINESSWIRE
FDA staff flag concerns with cancer treatments from Spectrum, Oncopeptides
21 Sep 2022 //
REUTERS
Spectrum Announces Data from Presentation for Poziotinib in NSCLC Patients
10 Sep 2022 //
BUSINESSWIRE
Spectrum Announces Presentation for Poziotinib in NSCLC Patients
05 Sep 2022 //
BUSINESSWIRE
Hanmi to start confirmatory NSCLC trial of poziotinib in Korea
17 Aug 2022 //
KOREABIOMED
Spectrum Pharmas Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
BUSINESSWIRE
Spectrum Pharma Presents Positive Data for Poziotinib in First-line NSCLC
07 Mar 2022 //
BUSINESSWIRE
Spectrum Pharmaceuticals Announces an Oral Poziotinib Presentation
28 Feb 2022 //
BUSINESSWIRE
Spectrum Pharmaceuticals Announces Strategic Restructuring
05 Jan 2022 //
BUSINESSWIRE
Spectrum Pharmaceuticals Announces New Strategic Investment by Hanmi Pharma
04 Jan 2022 //
BUSINESSWIRE
Foreign partners hurry to commercialize Hanmi’s new anticancer drugs
10 Nov 2021 //
KOREABIOMED
Spectrum Presents Late Breaker Oral Presentation of Poziotinib Data
19 Sep 2021 //
BUSINESSWIRE
Esmo 2021 – poziotinib could add first-line string to its bow
17 Sep 2021 //
EVALUATE
Spectrum To Present Data of Poziotinib in First-Line NSCLC Patients at ESMO 2021
13 Sep 2021 //
BUSINESSWIRE
Spectrum Pharmaceuticals to Present Data for Poziotinib
28 May 2021 //
BUSINESSWIRE
FDA Grants Fast Track Status to Poziotinib for HER2 Exon 20–Mutated NSCLC
11 Mar 2021 //
ONCLIVE
Spectrum Pharma Presents Results of Cohort 2, Poziotinib ZENITH20 Clinical Trial
18 Sep 2020 //
BIOSPACE
Spectrum Pharma Announces Positive Topline Results in HER2 Exon20 Insertion
27 Jul 2020 //
BUSINESSWIRE
Spectrum Provides Strategy Update for Poziotinib Development Program
28 Apr 2020 //
BUSINESSWIRE
Spectrum Provides Strategy Update for Poziotinib Development Program
27 Apr 2020 //
BUSINESSWIRE
Spectrum to Present Data from Phase 2 Clinical Trial for Poziotinib
21 Apr 2020 //
BUSINESSWIRE
Spectrum Pharma announces publication of positive poziotinib data in cancer cell
04 Oct 2019 //
SEEKINGALPHA
Spectrum Pharmaceuticals sells marketed drugs to Aurobindo subsidiary for up to $300M
18 Jan 2019 //
MEDCITY NEWS
Spectrum`s Announces Licensing Agreement on Certain Methods of Use of Poziotinib
03 May 2018 //
BUSINESSWIRE
Spectrum Announces Publication of Poziotinib Data in Nature Medicine
23 Apr 2018 //
BUSINESSWIRE
Spectrum`s Highlights Data Showing Poziotinib Overcomes De Novo HER2 Exon
17 Apr 2018 //
BUSINESSWIRE
Spectrum Announces Update of MD Anderson’s Phase 2 Data Studying Poziotinib
10 Apr 2018 //
INVESTOR
What To Expect After Spectrum Pharmaceuticals` Robust Earnings
08 Aug 2017 //
SEEKINGALPHA
